Abstracts tagged "ANCA"

Abstract Number: 2642 • 2019 ACR/ARP Annual Meeting
ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA
‪Gabriel Breuer‬‏¹, Bashar Fteiha ¹, Alon Benaya ¹, Marwan Abu Sneineh‬‏ ¹ and Gideon Nesher ¹, ¹Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel
Background/Purpose: With the widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. In addition to ANCA Associated Vasculitis (AAV),…
Abstract Number: 806 • 2019 ACR/ARP Annual Meeting
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Rona Smith¹, David Jayne ² and Peter Merkel ³, ¹University of Cambridge, Cambridge, England, United Kingdom, ²Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ³University of Pennsylvania, Philadelphia
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and relapse rates…
Abstract Number: 1680 • 2019 ACR/ARP Annual Meeting
Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Peter Merkel¹, Bernhard Hellmich ², David Jayne ³, Simon Rückinger ⁴, Zsuzsanna Tamas ⁵, Claus Thielert ⁵ and Othmar Zenker ⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ³Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ⁴Metronomia Clinical Research GmbH, Munich, Germany, ⁵InflaRx GmbH, Planegg, Germany, ⁶InflaRx GmbH, Jena, Germany
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are life-threatening rare autoimmune diseases to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Standard of care (SOC)…
Abstract Number: 2643 • 2019 ACR/ARP Annual Meeting
Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre
Lara Sanchez-Bilbao¹, Marina De Cos-Gomez ², Iñigo Gonzalez-Mazon ³, Belén Atienza-Mateo ¹, Jose Luis Martín-Varillas ¹, Mónica Calderón-Goercke ⁴, DIANA PRIETO- PENA ³, Juan Carlos Ruiz-San Millan ², Miguel A Gonzalez-Gay ¹ and Ricardo Blanco ¹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Nephrology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Rapidly Progressive Glomerulonephritis (RPGN) is characterized clinically by a rapid and severe decline in kidney function. Thus, this entity may lead to an end…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…
Abstract Number: 1762 • 2018 ACR/ARHP Annual Meeting
Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis
Catherine E. Najem¹, Martin Schmidt², Chad Stiening³, David Cuthbertson⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux¹², Philip Seo¹³, Ulrich Specks¹⁴, Antoine G. Sreih¹, Steven R. Ytterberg¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Kypha, Inc., St. Louis, MO, ³Kypha, Inc., St Louis, MO, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹³Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose:C3, the central protein of the complement cascade, participates in an amplification loop that can lead to complement deposition and host tissue damage. If elevated,…
Abstract Number: 2727 • 2018 ACR/ARHP Annual Meeting
Prevalence of Clinical and Subclinical Ophthalmologic Manifestations in Association with Systemic Symptoms, Disease Activity and Damage in Patients with Granulomatosis with Polyangiitis
Andrea Hinojosa-Azaola¹, Annette García-Castro² and Alejandra Juárez-Flores³, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Ophthalmology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Ophthalmologic involvement in Granulomatosis with Polyangiitis (GPA) is present in 50-60% of the patients and can affect any part of the ocular glove and…
Abstract Number: 1763 • 2018 ACR/ARHP Annual Meeting
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Cassidy Strange², Elliot Friedman², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵, Gary Wu⁵ and Peter A. Merkel⁴, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:To explore the mechanisms by which an altered gut microbiota might predispose to ANCA-associated vasculitis (AAV), a comprehensive metabolic profiling of fecal and plasma bile…
Abstract Number: 2729 • 2018 ACR/ARHP Annual Meeting
Increased Risk of Cerebrovascular Accident Among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-Analysis of Cohort Studies
Patompong Ungprasert¹, Karn Wijarnpreecha² and Wisit Cheungpasitporn³, ¹Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ²Internal medicine, Bassett medical center, cooperstown, NY, ³Medicine, University of Mississippi Medical center, Jackson, MS
Increased Risk of Cerebrovascular Accident among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-analysis of Cohort StudiesAbstractBackground/Purpose: An increased risk of cardiovascular…
Abstract Number: 13 • 2018 ACR/ARHP Annual Meeting
Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies
Jeffrey R. Ord¹, Amy G. Clark¹ and Mary H. Foster², ¹Duke University Medical Center, Durham, NC, ²Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Patients with ANCA vasculitis and anti-glomerular basement membrane (GBM) nephritis (Goodpasture’s Disease) develop pathogenic autoantibodies (autoAb) that destroy the microvasculature in lungs and kidneys.…
Abstract Number: 1764 • 2018 ACR/ARHP Annual Meeting
The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis
Yoko Wada¹, Takeshi Kuroda², Masaaki Nakano³ and Ichiei Narita¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²Health Administration Center, Niigata University, Niigata, Japan, ³Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan
Background/Purpose: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are antagonistic ligands which bind with similar affinity to the extracellular domain of the tyrosine kinase with Ig-like and…
Abstract Number: 2731 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital
Shilpa Arora¹, Ambrish Athavale² and Peter Hart², ¹Medicine, John H Jr Stroger Hospital of Cook County, Chicago, IL, ²John H Jr Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis (RLV). We aimed to study the clinical features…
Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
John L. Niles¹, Peter A. Merkel², Lester Mertz³, Patricia B. Lehane⁴, Pooneh Pordeli⁵ and Félix Erblang⁶, ¹Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ⁶Hoffmann-La Roche Ltd., Basel, Switzerland
Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis
Yasuhiro Shimojima¹, Dai Kishida² and Yoshiki Sekijima², ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
Abstract Number: 2732 • 2018 ACR/ARHP Annual Meeting
Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center
Mehmet Nedim Taş¹, Mete Kara¹, Sertaç Ketenci¹, Mete Pekdiker², Raika Durusoy³, Fikret Bademkıran⁴, Gokhan Keser⁵ and Kenan Aksu⁵, ¹Rheumatology, Ege University Medical Faculty, izmir, Turkey, ²Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, ³Public Health, Ege University Medical Faculty, izmir, Turkey, ⁴Neurology, Ege University Medical Faculty, izmir, Turkey, ⁵Rheumatology, Ege University Medical Faculty, Izmir, Turkey
Background/Purpose: Among many other organs and systems, ANCA-associated vasculitis (AAV) may also affect nervous system in up to more than half of patients, resulting in…

« Previous Page
1
…
6
7
8
9
10
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].